title: Cell-type-specific responses to chemotherapeutics in breast cancer.
abstract: Recent microarray studies have identified distinct subtypes of breast tumors that arise from different cell types and that show statistically significant differences in patient outcome. To gain insight into these differences, we identified in vitro and in vivo changes in gene expression induced by chemotherapeutics. We treated two cell lines derived from basal epithelium (immortalized human mammary epithelial cells) and two lines derived from luminal epithelium (MCF-7 and ZR-75-1) with chemotherapeutics used in the treatment of breast cancer and assayed for changes in gene expression using DNA microarrays. Treatment doses for doxorubicin and 5-fluorouracil were selected to cause comparable cytotoxicity across all four cell lines. The dominant expression response in each of the cell lines was a general stress response; however, distinct expression patterns were observed. Both cell types induced DNA damage-response genes such as p21(waf1), but the response in the luminal cells showed higher fold changes and included more p53-regulated genes. Luminal cell lines repressed a large number of cell cycle-regulated genes and other genes involved in cellular proliferation, whereas the basal cell lines did not. Instead, the basal cell lines repressed genes that were involved in differentiation. These in vitro responses were compared with expression responses in breast tumors sampled before and after treatment with doxorubicin or 5-fluorouracil/mitomycin C. The in vivo data corroborated the cell-type-specific responses to chemotherapeutics observed in vitro, including the induction of p21(waf1). Similarities between in vivo and in vitro responses help to identify important response mechanisms to chemotherapeutics.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 27599, USA.
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Troester
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Hoadley
authors.forename: Therese
authors.initials: T
authors.lastname: Sørlie
authors.forename: Brittney-Shea
authors.initials: BS
authors.lastname: Herbert
authors.forename: Anne-Lise
authors.initials: AL
authors.lastname: Børresen-Dale
authors.forename: Per Eystein
authors.initials: PE
authors.lastname: Lønning
authors.forename: Jerry W
authors.initials: JW
authors.lastname: Shay
authors.forename: William K
authors.initials: WK
authors.lastname: Kaufmann
authors.forename: Charles M
authors.initials: CM
authors.lastname: Perou
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001706:Biopsy; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000494:pharmacology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D020411:Oligonucleotide Array Sequence Analysis; D015533:Transcriptional Activation / Q000187:drug effects
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil